{"id":"W4366339435","doi":"10.1200/jco.22.01792","title":"Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Cilag; Foundation Medicine; Genentech; Eisai; Astellas Pharma; Eli Lilly and Company; Ono Pharmaceutical; G1 Therapeutics; GlaxoSmithKline; UroGen Pharma; Bavarian Nordic; Silverback Therapeutics; Ipsen; Mirati Therapeutics; Clovis Oncology; Janssen Biotech; Les Laboratories Pierre Fabre; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Gilead Sciences; Exelixis; Sanofi; Amgen; EUSA Pharma; AstraZeneca; Bristol-Myers Squibb","keywords":"Avelumab; Medicine; Clinical endpoint; Metastatic Urothelial Carcinoma; Hazard ratio; Internal medicine; Bladder cancer; Clinical trial; Progression-free survival; Oncology; Urothelial carcinoma; Chemotherapy; Cancer; Immunotherapy; Confidence interval; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002449607,0.0001909273,0.001530716,0.00009010969,0.00005025919,0.000008023585,0.0002854122,0.0003767373,0.0001322084],"category_scores_gemma":[0.008368188,0.000119011,0.001042753,0.000222559,0.0002410118,0.00007565464,0.00007087217,0.0006315042,0.00004337243],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000117129,"about_ca_system_score_gemma":0.001714492,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001517323,"about_ca_topic_score_gemma":0.0002871037,"domain_scores_codex":[0.9957916,0.0002603535,0.00281405,0.0003163652,0.0004643901,0.0003532713],"domain_scores_gemma":[0.9911423,0.006195354,0.001506224,0.0003958628,0.000516953,0.0002432531],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.801528,0.001292133,0.004112367,0.00002396038,0.001051477,0.0005725519,0.0007550091,0.00004072047,0.0001034301,0.00002208914,0.0353446,0.1551537],"study_design_scores_gemma":[0.5368831,0.03590474,0.1979698,0.0002358061,0.001467382,0.00005042358,0.0002812745,0.0001717614,0.0002621177,0.001674718,0.2248982,0.0002006172],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9769754,0.0003719537,0.0002192568,0.01458582,0.00583259,0.001092849,0.0004751877,0.00001716288,0.0004297698],"genre_scores_gemma":[0.9889063,0.00077733,0.001541779,0.002020439,0.004639117,0.00006154245,0.00002771121,0.00004063899,0.001985192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2646448,"threshold_uncertainty_score":0.9999847,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1206717529403053,"score_gpt":0.4287012932690438,"score_spread":0.3080295403287385,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}